Insmed Q3 2026 slides: BRINSUPRI hits blockbuster status

Insmed Inc. (INSM) reported Q3 2026 revenues of $524.4M, driven by BRINSUPRI's $400.1M (29% sequential growth) and ARIKAYCE's $124.4M. BRINSUPRI reached blockbuster status, raising full-year guidance to $1.35B-$1.4B. The stock rose 11.1% to $107.75 despite a $0.46 adjusted loss per share.

Original reporting
Published Oct 29, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INSM
Bullish
high confidence
Mentioned
$INSM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INSMBullishHigh
01

Why it matters

The earnings beat and guidance raise drove an 11% stock jump, indicating strong market reaction.

02

Market read

Earnings surprise and guidance lift make INSM a near‑term trade candidate with upside potential.

03

What to watch

Potential reimbursement challenges in international markets and competition from other respiratory therapies.

Relevance 8/10Novelty 8/10Timing: after-hours reaction to earnings release

Background

Insmed reported its Q3 2026 results, emphasizing blockbuster status for its new bronchiectasis drug and raising full‑year guidance.

Company-level read

Ticker impact

$INSMBullishHigh confidence
Context

Q3 2026 earnings posted $524.4M revenue, 11.1% stock surge to $107.75 and raised full‑year guidance to $1.35‑$1.40B, marking blockbuster status for BRINSUPRI.

Expected impact

likely upward pressure as investors price in higher revenue outlook and blockbuster launch momentum

Evidence & confidence

The earnings beat, revenue growth, and guidance raise are fresh, material facts that drove an 11% move; market typically rewards such biotech milestones.

Market effects

Boosts outlook for respiratory biotech and specialty pharma sector, may lift peers with similar pipelines.

Positive impact on US biotech indices; Japan market may see related gains as BRINSUPRI launches there.

Highlights growing demand for bronchiectasis treatments worldwide, could influence global specialty drug investors.

Counterpoint

The rapid revenue ramp may be unsustainable; high guidance could be revised down if launch momentum stalls.

Key entities

  • Insmed Incorporated

    US‑listed biotech company (NASDAQ:INSM) reporting Q3 2026 earnings.

Related articles

$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

$INSMHighAI 9/10

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

$INSMHighAI 8/10

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.